UNAX LERTXUNDI ETXEBARRIA-rekin lankidetzan egindako argitalpenak (41)

2024

  1. Acetazolamide-induced pulmonary oedema: A disproportionality analysis from the EudraVigilance database

    British Journal of Clinical Pharmacology, Vol. 90, Núm. 7, pp. 1751-1755

  2. Incorporating the One Health philosophy into pharmacovigilanc: Pharmacovigilance

    British Journal of Clinical Pharmacology

  3. Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance

    European Neuropsychopharmacology

  4. [Translated article] Pharmaceuticals in the environment: A hospital pharmacy perspective

    Farmacia Hospitalaria, Vol. 48, pp. TS13-TS20

2023

  1. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database

    European Journal of Clinical Pharmacology, Vol. 79, Núm. 5, pp. 679-685

2022

  1. Subacute thyroiditis and COVID-19 vaccines: a case/non-case study

    Endocrine, Vol. 77, Núm. 3, pp. 480-485

2021

  1. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study

    European Neuropsychopharmacology, Vol. 50, pp. 107-111

  2. Pharmacotherapeutic management of Parkinson's disease inpatients: How about asking hospital pharmacists?

    European Journal of Hospital Pharmacy, Vol. 28, Núm. e1, pp. E140-E145

  3. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database

    Journal of Clinical Pharmacology, Vol. 61, Núm. 2, pp. 187-192

  4. Tramadol-induced hiccups: a case–noncase study in the European pharmacovigilance database

    Therapeutic Advances in Drug Safety, Vol. 12

2019

  1. Antipsychotics and pituitary tumors: An analysis of the European pharmacovigilance database (EudraVigilance)

    International Clinical Psychopharmacology, Vol. 34, Núm. 2, pp. 89-92

  2. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database

    American journal of therapeutics, Vol. 26, Núm. 5, pp. e589-e592

2018

  1. Aripiprazole and impulse control disorders: Higher risk with the intramuscular depot formulation?

    International Clinical Psychopharmacology, Vol. 33, Núm. 1, pp. 56-58

2017

  1. Clozapine-Induced Cardiomyopathy in Parkinson's Disease

    Movement Disorders Clinical Practice

  2. El hipo en la Enfermedad de Parkinson

    Congreso SEFIG (13º. Alcalá de Henares. 2017)

  3. Hiccups in Parkinson’s disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature

    European Journal of Clinical Pharmacology, Vol. 73, Núm. 9, pp. 1159-1164

  4. Medication errors in Parkinson's disease inpatients in the Basque Country

    Parkinsonism and Related Disorders, Vol. 36, pp. 57-62

2016

  1. Beers 2015 Criteria: Aripiprazole in Parkinson′s Disease

    Journal of the American Geriatrics Society

  2. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: A case report and analysis of cases reported in the European pharmacovigilance database

    Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 3, pp. 368-370

2015

  1. Adverse reactions to antipsychotics in parkinson disease: An analysis of the Spanish Pharmacovigilance database

    Clinical Neuropharmacology, Vol. 38, Núm. 3, pp. 69-84